Abstract. Since resveratrol is not a potent cytotoxic compound when compared with other chemotherapeutic agents, several previous studies have been performed to obtain synthetic analogs of resveratrol with potent activity. Our previous study demonstrated that the resveratrol analog HS-1793 showed stronger antitumor activity than resveratrol in various cancer cells. We examined the antitumor activity exerted by HS-1793 in prostate cancer cells, and we observed that HS-1793 acts as a polyploidy inducer. Noticeably, multinucleation and polyploidization were induced in most LNCaP cells treated with HS-1793 at the dose causing a slight decline in cell viability. However, the induction of multinucleation and polyploidization was much lower in PC-3 prostate cancer cells treated with the same dose of HS-1793. Western blot and RT-PCR analyses showed that the expression of Aurora B was almost undetectable in LNCaP cells, but it was highly expressed in PC-3 cells. Further, silencing of Aurora B sensitized PC-3 cells to HS-1793-induced multi-nucleation. These results indicate that expression of Aurora B determines multinucleation in prostate cancer cells treated with HS-1793. Additional assays using multiple cancer cell lines show that the population of multinucleated cells induced by HS-1793 treatment is inversely proportional to Aurora B expression. We further elicited that the HS-1793-induced polyploid LNCaP cells are vulnerable to downregulation of Bcl-xL. Since the polyploidization in LNCaP induced by HS-1793 does not appear to cause definite commitment to apoptosis, the termination of polyploid cells by inhibition of Bcl-xL could provide an advantageous means to improve chemotherapeutic efficacy of HS-1793.
Introduction
The polyphenolic compound resveratrol (3,5,4-trihydroxytrans-stilbene) is a naturally occurring phytochemical found in food products such as grapes, peanuts, and various herbs. Resveratrol acts on the process of carcinogenesis by affecting cellular events associated with tumor initiation, promotion, and progression (1) . Resveratrol is also able to induce apoptosis (2) . The chemopreventative and chemotherapeutic properties associated with resveratrol offer promise for the design of new chemotherapeutic drugs. However, resveratrol is not a potent cytotoxic compound when compared with other chemotherapeutic agents. Therefore, exposure to high doses of resveratrol is required to exert antitumor efficacy (3) . Furthermore, the biological activity of resveratrol is limited by its photosensitivity and metabolic instability (4) . Accordingly, several previous studies have been performed to test synthetic analogs of resveratrol with potent activity.
Our previous study, using four resveratrol analogs designed and synthesized by us (5) , demonstrated that those analogs showed stronger antitumor activity than resveratrol in various cancer cells (6) . We elucidated that the antitumor activity of a resveratrol derivative 4-(6-hydroxy-2-naphthyl)-1,3-benzenediol (HS-1793) is mediated by the downregulation of 14-3-3 in human leukemic U937 cells.
Prostate cancer (CaP) develops in the tissues of the prostate gland in the male reproductive system. It is one of the most common cancers in men and is the second leading cause of male cancer mortality worldwide after lung cancer (7) . Previous studies have reported that resveratrol, a naturally occurring phytoalexin found in red wine, grapes, peanuts, and a variety of medicinal plants, has the ability to inhibit the carcinogenic process at initiation, promotion, and progression and induce apoptosis in various tumor cells, including prostate cancer cells (1, (8) (9) (10) . It has been reported that resveratrol inhibits CaP cell proliferation and suppresses the expression of prostate specific genes such as prostate-specific antigen (PSA) and the androgen receptor (AR) (11) . In addition, several potential targets of resveratrol have been reported, including NF-κB, AP-1, p53, Bcl-2 and Bax, but the mechanism by which resveratrol inhibits cancer cell growth is still not fully understood (8, 10) . The antitumor effects of resveratrol analogs on prostate cancers have also been studied (8, 10) . Aurora kinases are serine/threonine protein kinases that regulate several processes during cell division such as chromosome alignment, segregation, and cytokinesis. Mammalian cells express three Aurora kinases: Aurora A, B and C (12) . The three Aurora kinases are highly similar in sequence and structure. However, the three mammalian Aurora kinases are known to be different in their subcellular distribution and functions (13) . Aurora A localizes to the spindle poles where it plays an important role in centrosome separation, mitotic entry, and spindle assembly (14) . Aurora B is a key regulator of chromosome alignment, microtubule-kinetochore attachment, spindle check point, and cytokinesis (13, 14) . Less is known about Aurora C, which is specifically expressed at high levels in the testes and localizes to centrosomes from anaphase to telophase (15) .
Significant overexpression of Aurora B has been shown in a wide range of human cancer cells (16) . In addition, elevated levels of Aurora kinases correlate with advanced clinical stages of cancers (17) . Therefore, Aurora kinases have become propitious targets for cancer therapy and are being evaluated in clinical trials for the treatment of cancer. Several small molecule inhibitors of Aurora kinases have been developed including ZM447439 (Astra Zeneca), Hesperadin (Boehringer Mannheim), vX-680 (vertex Inc.), and AZD1152 (17, 18) . The typical cellular phenotype induced by the inhibition of Aurora B is a failure of normal cytokinesis with the induction of polyploidy and multinucleated giant cells (19) . Pharmacological incapacitation of the spindle assembly checkpoint with small-molecule Aurora B inhibitors induces apoptosis secondary to polyploidization (18, 20) . Thus, Aurora B inhibitors are being evaluated in clinical trials for the treatment of cancer. Aurora kinase expression appears to influence prostate cell proliferation (17) , and Aurora kinase expression directly correlates with prostate cancer malignancy (17, 21) . While Aurora B is highly expressed in PC-3 prostate cancer cells, its expression in LNCaP prostate cancer cells is much weaker than in PC-3 cells or almost undetectable (17) .
We performed this study to examine the mechanism underlying the antitumor activity of HS-1793 in prostate cancer cells. HS-1793 induces the formation of multinucleated polyploid cells in LNCaP human prostate cancer cells. Further, HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL. Preparation of resveratrol analogs. HS-1793 was prepared as described previously (6) .
Materials and methods

Reagents
Cell culture. Human prostate cancer cells PC-3 and LNCaP and other cancer cells k562, U937, HCT116 and T98G were obtained from the American Type Culture Collection (ATCC, Rockville, MD). ZR-75-1 and U373MG were purchased from the korean Cell Line Bank (kCLB, Seoul, korea). The anaplastic thyroid cancer cell line kAT-18 was kindly provided by Dr k.B. Ain (University of kentucky, Chandler Medical Center, Lexington, kY). The culture medium used throughout these experiments was RPMI-1640 medium with 10% fetal calf serum (FCS), 20 mM HEPES buffer and 100 µg/ml gentamicin.
Resveratrol analog treatment and assessment of cell viability.
Resveratrol analogs (10 µM) in ethanol were prepared and stored at -80˚C until use. Cells were treated with resveratrol analogs (up to 40 µM). Cells were harvested 48 h after treatment, and cell viability was determined with the vi-Cell cell counter (Beckman Counter, Fullerton, CA), which performs an automated trypan blue exclusion assay.
Nuclear morphology analysis of apoptosis. The cell suspension was cytospun onto clean fat-free glass slides with a cytocentrifuge. Cytocentrifuged samples were fixed for 10 min in 4% paraformaldehyde solution and stained in 4 µg/ml of Hoechst 33342 for 30 min at 4˚C. The cells were observed and photographed under an epifluorescence microscope. To quantify cells showing multinucleation, the total cell number (300 cells from each experiment) was counted using differential interference contrast (DIC) optics by an observer who was blinded to the experimental group.
Reverse transcriptase (RT)-PCR.
Total cellular RNA was isolated from different cell lines using the RNeasy Mini kit (Qiagen, GmbH, Germany). Total RNA (2 µg) was reversetranscribed using oligo-dT primers and M-MLv reverse transcriptase. Approximately 1 to 3 µl of reverse transcription-PCR reactions were subjected to 30 cycles of PCR for amplification of Aurora B and β-actin. The PCR was performed in a 50 µl reaction volume containing 1 µM primers, 200 µM of each dNTPs and 1.25 units of Taq DNA polymerase. After denaturing at 95˚C for 2 min, cDNA was subjected to 30 cycles of PCR amplification. The PCR conditions were 95˚C for 40 sec, 60˚C for 40 sec and 72˚C for 100 sec for Aurora B and β-actin amplification with a final extension of 72˚C for 5 min. The PCR-amplified products were electrophoresed in a 1% or 1.5% agarose gel and stained with ethidium bromide. Expression was standardized using the β-actin signal as an internal control. The sequence of oligonucleotide primers is as follows: Aurora B-forward primer, 5'-CGACATCTTAACGCGGCAC-3'; Aurora B-reverse primer, 5'-GGACGCCCAATCTCAAAGTC-3' (50 bp fragments); β-actin-forward primer, 5'-TGACGGGGTCACCCACACT GTGCCCAT-3'; and β-actin-reverse primer, 5'-CTAGAAG CATTTGCGGTGGACGATGGAGGG-3' (660 bp fragments).
Flow cytometric analysis. Ice-cold 95% ethanol supplemented with 0.5% Tween-20 was added to cell suspensions to a final concentration of 70% ethanol. Fixed cells were pelleted and washed in 1% BSA-PBS solution. The cells were re-suspended in 1 ml PBS containing 11 Kunitz U/ml RNase, incubated at 4˚C for 30 min, washed once with BSA-PBS, and re-suspended in a PI solution (50 µg/ml). The cells were incubated at 4˚C for 30 min in the dark and were then filtered through 35 mm mesh, and the DNA content was determined using a FACSCalibur (Becto-Dickinson) flow cytometer within 1 h. The cellular DNA content was analyzed by CellQuest software (BectonDickinson).
Western blot analysis. Cell lysates were centrifuged at 14,000 rpm for 15 min at 4˚C. The protein concentrations of the cell lysates were determined using a Bradford protein assay (Bio-Rad), and equal amounts of proteins were loaded onto 7.5-15% SDS-polyacrylamide gels. The gels were transferred to nitrocellulose membranes (Amersham Pharmacia Biotech, Piscataway, NJ) and blotted with each antibody. Immunostaining with antibodies was performed using Super Signal West Pico enhanced chemiluminescence substrate and detected with LAS-3000PLUS (Fuji Photo Film Company, kanagawa, Japan).
siRNA transfection. To determine the effect of Aurora B knockdown, the following double-stranded RNA oligonucleotides were used: sense: 5'-AAGGAGAACUCCUACCC CUGGUU-3', antisense: 5'-CCAGGGGUAGGAGUUCUCU UUU-3'. For Bcl-2, Mcl-1, and Bcl-xL depletion, pre-designed siRNA constructs were purchased. As a negative control, the same nucleotides were scrambled to form non-targeting combinations. All of the siRNA duplexes were synthesized by Dharmacon (Chicago, IL) and were transfected using siPORT Amine (Ambion, TX) in OptiMEM (Bio Sciences, Dublin, Ireland) according to the manufacturer's recommendations.
Live cell imaging. Live LNCaP cells were plated on 35 mm dishes 24 h prior to treatment. Hoechst 33342 solution was added in the tissue culture media at 3 µg/ml for 30 min. The cells were then washed and cultured with HS-1793 at 10 µM. Live cell observation was performed in a temperature controlled chamber for 17 h using an integrated Delta vision system (Applied Precision, Issaquah, WA). For monitoring multinucleation, at least 5 fields containing 3 to 7 cells were observed.
Giemsa staining. LNCaP cells were cultured without or with HS-1793 and then fixed with 3:1 methanol/acetic acid for 10 min. For polyploidy observation, slides were stained for 10 min with Giemsa solution.
Statistical analysis. Four independent in vitro experiments were carried out. Statistical results were expressed as the mean ± SD of the means obtained from triplicates of each independent experiment. Statistical significance of differences was determined by the paired kruskal-Wallis non-parametric test. P<0.05 was considered significant.
Results
HS-1793 induces multinucleation and polyploidization in
LNCaP human prostate cancer cells. As determined by trypan blue assay, HS-1793 reduced the viability of human prostate cancer LNCaP cells in a dose-dependent manner. To further study the mechanism of the cytotoxicity induced by HS-1793, LNCaP cells were cultured in the absence or presence of HS-1793 at 10 µM, which is the lowest dose that caused a decline (approximately 20%) in cell viability 48 h after treatment. Western blot assay showed degradation of caspase-3, indicating that HS-1793 reduced the viability of human prostate cancer LNCaP cells via the caspase-mediated pathway (Fig. 1B) . Noticeably, HS-1793 induced multinucleation in LNCaP cells. Forty eight hours after treatment with HS-1793, most LNCaP cells were multinucleated (Fig. 1C and D) . Using live cell imaging, we were able to directly observe the formation of a multinucleated cell after treatment with HS-1793. The increase in the number of nuclei was a continuous process (Fig. 1E) . Flow cytometry demonstrated that LNCaP cells became fully octaploid (8c) by 48 h, as shown by an 8c DNA peak (Fig. 1F) . We further examined the expression level of p53 protein, which is a substitute cellular marker of polyploidization in cells with wild-type p53 genetic status. As expected, the expression level of p53 was substantially increased in HS-1793-treated polyploid LNCaP cells (Fig. 1G) . caspase-3 (Fig. 2B) . Intriguingly, the induction of multinucleation and polyploidization by HS-1793 was much lower in PC-3 cells than in LNCaP cells. Morphological observation showed that HS-1793 did not substantially increase the population of multinucleated cells in PC-3 cells. The percent of multinucleated cells 48 h after treatment was less than 10% (Fig. 2C) . Flow cytometry also demonstrated that HS-1793 did not substantially increase the population of polyploid cells (Fig. 2D) . The percent of polyploid cells 48 h after treatment was less than 10%.
HS-1793 did not substantially induce multinucleation in
Expression of Aurora B determines multinucleation in prostate cancer cells treated with HS-1793.
We next examined whether the expression of Aurora B determines multinucleation in prostate cancer cells treated with HS-1793. Western blot analysis showed that the expression of Aurora B is almost undetectable in LNCaP cells, while it is highly expressed in PC-3 cells (Fig. 3A) . We next examined whether knock-down of Aurora B sensitized PC-3 human prostate cancer cells to the induction of multinucleation by HS-1793. The introduction of siRNA against Aurora B efficiently depleted Aurora B in PC-3 cells (Fig. 3A) . Importantly, siRNA against Aurora B significantly increased the population of multinucleated cells in PC-3 cells treated with HS-1793 compared to the control and the experimental control (Fig. 3C) . The effect of Aurora B siRNA on the population of multinucleated cells in LNCaP cells was examined 24 h after HS-1793 treatment. Treatment with siRNA against Aurora B did not alter the population of multinucleated cell in LNCaP cells ( Fig. 3D and E) .
The population of multinucleated cells after HS-1793 treatment is inversely proportional to Aurora B expression.
To further address the relationship between the incidence of multinucleated polyploid cells induced by HS-1793 and the expression of Aurora B, reverse transcriptase (RT)-PCR was performed with gene-specific primers for Aurora B. Our RT-PCR analysis demonstrated that unlike seven cancer cell lines showing high expression of Aurora B mRNA, LNCaP and T98G cancer cells showed much lower expression of Aurora B mRNA (Fig. 4A) . Western blot assay showed that the expression of Aurora B protein was also much lower in T98G cells compared to seven other cancer cells (Fig. 4B) . The expression of Aurora B mRNA and protein was almost undetectable in LNCaP cells. Importantly, the number of multinucleated cells induced by HS-1793 treatment was significantly higher in T98G cells compared to seven other cancer cell lines with high expression of Aurora B (Fig. 4C) . However, the population of multinucleated cells in T98G treated with HS-1793 was significantly lower than in HS-1793-treated Aurora B-depleted LNCaP cells. These findings indicate that the population of multinucleated polyploid cells induced by HS-1793 treatment is inversely proportional to Aurora B expression.
HS-1793 and inhibition of Bcl-xL elicit synergistic cytotoxicity.
Because recent studies have demonstrated that the inhibition of Bcl-xL triggers accelerated death of polyploid cancer cells (22) , we further examined whether combined treatment of HS-1793 with ABT-263, which inhibits Bcl-2 family members including Bcl-xL, could trigger significant cytotoxicity. While 1 µM ABT-263 treatment alone did not reduce the viability of LNCaP cells, 1 µM ABT-263 in combination with 10 µM HS-1793 augmented the death induced by HS-1793. Further, the combination treatment produced cleaved caspase-3 at earlier time points compared to HS-1793 alone (Fig. 1B) . Because ABT-263 inhibits several members of the Bcl-2 family, we next used siRNA to determine which of the ABT-263 targets, when inhibited, would be responsible for the synergistic cytotoxicity exerted by ABT-263 in combination with HS-1793. siRNAs against Bcl-2, Mcl-1 and Bcl-xL efficiently downregulated the expression of their target proteins in LNCaP cells. Silencing of Bcl-2 or Mcl-1 slightly reduced the viability of LNCaP cells regardless of HS-1793 treatment. Importantly, although siRNA against Bcl-xL decreased the viability of untreated LNCaP cells, it significantly reduced the viability of LNCaP cells treated with HS-1793 compared with siRNA against Bcl-2 or Mcl-1, indicating that synergistic activity of HS-1793 and ABT-263 is mainly due to the inhibition of Bcl-xL (Fig. 5C ).
Discussion
Polyploidy emerges from various defects in DNA replication, dissolving sister-chromatid cohesion, mitotic spindle function or cytokinesis (23) (24) (25) (26) . Polyploid cells are formed during normal development and in several pathological conditions (26) . Cells become polyploid through a mechanism involving incomplete cell division (27) . Although a proportion of hepatocytes are polyploid during normal development in mammals, a remarkable increase in the percentage of polyploid hepatocytes is observed in response to stress or injury (26) . Moreover, heart muscle and vascular smooth-muscle cells, which are normally diploid, become polyploid in either rats or humans with hypertension (27, 28) . However, it is not clear whether polyploidy is an adaptive or pathological response to these conditions.
It is believed that polyploidy plays a critical role in the development of genome instability and tumorigenesis (29) . Polyploidy is often observed in cancer cells, but it is not clear whether this phenomenon is a cause or result of cancer development (26, 30, 31) . Previous studies showed that the failure of cytokinesis results in cell polyploidy and subsequent cell death (32) and that freshly generated polyploid cells are prone to undergo Bax-dependent mitochondrial membrane permeabilization and subsequent apoptosis (33) . Polyploidization makes tumor cells more vulnerable to certain types of DNA damage, and increased polyploidy increases the sensitivity of cells to DNA-damaging agents (34) . These findings suggest that, although polyploidy is involved in the development of neoplasia through genomic instability, it may also prove to be a new approach to cancer therapy. Conversely, polyploid cells may be resistant to DNA-damaging agents (33) .
The present study elucidated that HS-1793 acts as an inducer of polyploidy. HS-1793 showed an exceptional ability to turn a non-synchronous population of proliferating cancer cells into a population with various degrees of polyploid cells (5 to 99%) that is inversely proportional to Aurora B expression in multiple human cancer cells. Intriguingly, HS-1793 seems to exert polyploidy-inducing activity independent of Aurora B inhibition. Our Western blot assay showed that HS-1793 did not alter the expression level of Aurora B protein of the cancer cells we tested (negative data not shown). Furthermore, whereas HS-1793 efficiently induced polyploidy in Aurora B-depleted cells, it did not efficiently induce polyploidy in cells that express high levels of Aurora B. To date, several chemicals, including chemotherapeutic agents (22, (35) (36) (37) , have been shown to induce polyploidy in cancer cells. Among these, some agents can induce polyploidization independent of Aurora kinase inhibition, although most of these chemicals induce chromosome missegregation and cytokinesis failure through the loss of Aurora B, resulting in cell polyploidy. Thus, deciphering the detailed molecular mechanism by which HS-1793 induces polyploidization independent of Aurora B inhibition is an important and challenging task.
Intriguingly, the polyploidization induced by HS-1793 does not appear to cause definite commitment to apoptosis. Although approximately 100% of LNCaP cells displayed multinucleation 48 h after treatment with 10 µM HS-1793, over 3/4 of them were viable. Previous studies demonstrated that polyploidization is a genomic change that is thought to facilitate evolution through increased gene dosage, the capacity to overcome deleterious mutations, and increased genomic instability (38) . This unexpected process infrequently generates viable progeny with normal fates, albeit far less frequently than diploid cells (39) . Therefore, the induction of polyploidy in tumor cells may itself accelerate adaptation to and escape from chemotherapeutic agents, resulting in the evolution of more aggressive secondary tumors via genetic reshuffling. Thus, the termination of polyploid cells could provide an advantageous means to improve the efficacy of chemotherapeutic agents while minimizing the risk of genetically adapted tumor cells after chemotherapy.
Previous studies demonstrated that Bcl-xL/-2 supports viability during polyploidization (22, 24) . A study showed that ectopic expression of Bcl-xL provides a survival advantage to polyploid murine FL5.12 cells after mitotic spindle damage (24) . Another study showed that the combination of polyploidy inducers and agents targeting Bcl-xL exhibited synergistic antitumor activity. Further study of the mechanism by which Bcl-xL neutralization elicits cell death in polyploid cells showed that polyploidization shifts the burden to support viability from Mcl-1 to Bcl-xL (22) . In the present study, we showed robust synergistic antitumor activity in LNCaP cells treated with HS-1793 in combination with ABT-263. Further, in line with previous hypotheses (22) , siRNA-mediated knockdown of Bcl-xL but not Bcl-2 or Mcl-1 leads to enhanced polyploid-induced cell death by HS-1793. These data indicate that polyploidization in LNCaP cells induced by HS-1793 also may shift the burden to support viability to Bcl-xL. Down-regulation of Bcl-xL contributes to the vulnerability of tumor cells during polyploidization, suggesting that this may represent a new approach to preventing the evolution of secondary tumors that might be more prone to resist therapy. Thus, the elimination of polyploid cells can improve the efficacy of HS-1793 while minimizing the development of secondary tumors after chemotherapy. Combining HS-1793 with ABT-263 warrants further attention as a potential chemotherapeutic intervention in cancer cells that weakly express Aurora B.
Unlike HS-1793, resveratrol at the same dose does not induce multinucleation in LNCaP cells. In previous reports, the potency of stilbene analogs has been shown to depend on the chemical structure. Stilbene analogs with higher potency than resveratrol may have preferential interaction with the receptor (6) . In addition, modulation of the activity of several genes or kinases or preferential subcellular localization due to the chemical configuration of the stilbene analogs may cause potent apoptosis-inducing activity (40, 41) . HS-1793 does not contain the unstable double bond that is found in resveratrol, and the position of two of three hydroxyl groups in HS-1793 at the aromatic ring is different from resveratrol. Thus, although we assume that these configurations of HS-1793 might confer poly-ploidization activity, the structure-function effects of HS-1793 remain to be clarified.
In summary, we demonstrated here that the resveratrol analogue HS-1793 induces polyploidy in cancer cells that weakly express Aurora B. Further, polyploidization induced by HS-1793 is vulnerable to the downregulation of Bcl-xL.
